"We are pleased to have Dr. Crapo join our management team at a significant time in Omni Bio's development," stated Vicki Barone, Chairperson of Omni Bio's Board of Directors. "James brings a world-renowned medical reputation and hands-on strategic business experience that Omni Bio requires going forward. We continue to be deeply indebted to Dr. Dinarello for the precious time that he has dedicated to Omni Bio both on the business and scientific fronts over the past two years as CEO. We look forward to Charles continuing the furtherance of the Company's science and clinical trial opportunities in his new capacity as Chief Scientific Officer and Chief Medical Director."
Edward Larkin, Omni Bio's Chief Operating Officer, commented, "As Omni Bio's first CEO, Dr. Dinarello's contributions have been enormous. Under his leadership, Omni Bio's intellectual property has become more focused on immunological diseases, which directly led to our ability to conduct our current human clinical trial in Type 1 diabetes. This clinical trial is progressing favorably in its early stage, in large part due to Dr. Dinarello's efforts in forging a strategic relationship with one of the four manufacturers of the trial drug, AAT, to supply AAT to Omni Bio at no cost for use in the trial. We also are in discussions with the Barbara Davis Center for Childhood Diabetes related to expanding the Type 1 diabetes clinical trial to 50 patients, contingent upon our raising additional capital. The expansion of the trial could involve our including an additional center for patient enrollment, and potentially initiating double blind enrollment for the new patient enrollments going forward."
Over the course of the
|SOURCE Omni Bio Pharmaceutical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved